Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

OTHER 13NETWORK 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 1CNS 1Breast 1

Conditions

Melanoma 1Glioblastoma 1Breast Neoplasms 1Astrocytoma 1

Interventions

pembrolizumab 604Carboplatin 372Paclitaxel 282Cisplatin 267Gemcitabine 252Pemetrexed 193Bevacizumab 190Docetaxel 185Nivolumab 181Injections 167Cyclophosphamide 147atezolizumab 138Fluorouracil 133Capecitabine 133Oxaliplatin 132Dexamethasone 127Fulvestrant 113durvalumab 112130-nm albumin-bound paclitaxel 110fludarabine 101Cetuximab 100Leucovorin 97Rituximab 94venetoclax 90Lenalidomide 83enzalutamide 77Prednisone 76Azacitidine 74Irinotecan 72Ipilimumab 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Eflornithine × 1 year × Clear all
NCT07287917 2026-05-12

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

Aminex Therapeutics, Inc.

Phase 1/2 Recruiting
92 enrolled
BreastDermatologic

Breast Neoplasms, Melanoma

NCT05879367 2025-06-25

Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

Orbus Therapeutics, Inc.

Phase 1 Recruiting
66 enrolled
CNS

Astrocytoma, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡